<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">762</article-id><article-id pub-id-type="doi">10.54101/ACEN.2021.3.10</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Clinical analysis</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинический разбор</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">A case of pseudodominant inheritance of limb-girdle muscular dystrophy caused by mutations in the CAPN3 gene</article-title><trans-title-group xml:lang="ru"><trans-title>Случай псевдодоминантного наследования поясно-конечностной мышечной дистрофии, обусловленной мутациями в гене CAPN3</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5819-4835</contrib-id><name-alternatives><name xml:lang="en"><surname>Sharkova</surname><given-names>Inna V.</given-names></name><name xml:lang="ru"><surname>Шаркова</surname><given-names>Инна Валентиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), leading researcher, Scientific advisory department</p></bio><bio xml:lang="ru"><p>к.м.н., в.н.с. научно-консультативного отд.</p></bio><email>sharkova-inna@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8674-7230</contrib-id><name-alternatives><name xml:lang="en"><surname>Bulakh</surname><given-names>Maria V.</given-names></name><name xml:lang="ru"><surname>Булах</surname><given-names>Мария Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), researcher, DNA diagnostics laboratory</p></bio><bio xml:lang="ru"><p>к.м.н., н.с. лаб. ДНК-диагностики</p></bio><email>sharkova-inna@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5946-4577</contrib-id><name-alternatives><name xml:lang="en"><surname>Bessonova</surname><given-names>Liudmila А.</given-names></name><name xml:lang="ru"><surname>Бессонова</surname><given-names>Людмила Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>geneticist, Advisory department</p></bio><bio xml:lang="ru"><p>врач-генетик Консультативного отд.</p></bio><email>sharkova-inna@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4905-1303</contrib-id><name-alternatives><name xml:lang="en"><surname>Shchagina</surname><given-names>Olga A.</given-names></name><name xml:lang="ru"><surname>Щагина</surname><given-names>Ольга Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), leading researcher, DNA diagnostics laboratory</p></bio><bio xml:lang="ru"><p>к.м.н., в.н.с. лаб. ДНК-диагностики</p></bio><email>sharkova-inna@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5602-2805</contrib-id><name-alternatives><name xml:lang="en"><surname>Dadaly</surname><given-names>Elena L.</given-names></name><name xml:lang="ru"><surname>Дадали</surname><given-names>Елена Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Head, Scientific advisory department</p></bio><bio xml:lang="ru"><p>д.м.н., проф., зав. научно-консультативного отд.</p></bio><email>sharkova-inna@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Centre for Medical Genetics</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Медико-генетический научный центр имени академика Н.П. Бочкова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-10-04" publication-format="electronic"><day>04</day><month>10</month><year>2021</year></pub-date><volume>15</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>85</fpage><lpage>91</lpage><history><date date-type="received" iso-8601-date="2021-10-04"><day>04</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-04"><day>04</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Sharkova I.V., Bulakh M.V., Bessonova L.А., Shchagina O.A., Dadaly E.L.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Шаркова И.В., Булах М.В., Бессонова Л.А., Щагина О.А., Дадали Е.Л.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Sharkova I.V., Bulakh M.V., Bessonova L.А., Shchagina O.A., Dadaly E.L.</copyright-holder><copyright-holder xml:lang="ru">Шаркова И.В., Булах М.В., Бессонова Л.А., Щагина О.А., Дадали Е.Л.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/762">https://annaly-nevrologii.com/pathID/article/view/762</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Limb-girdle muscular dystrophy (LGMD) includes more than 30 forms caused by mutations in genes located on autosomes. The most common form is calpain-3-related LGMD, with autosomal recessive inheritance pattern (OMIM 253600). An autosomal dominant form of LGMD (OMIM 618129) caused by c.643_663del heterozygous mutation in the CAPN3 gene is also supposed to exist.</p> <p>This article describes a family case of LGMD caused by mutations in the CAPN3 gene with pseudodominant inheritance.</p> <p><bold>Materials and methods. </bold>Two patients with LGMD were studied: a 59-year-old woman and her 38-year-old daughter. Clinical, genealogical and molecular genetics methods were used: limb girdle muscular dystrophy MPS panel, Sanger sequencing of DNA of the proband, her affected daughter, and six first- and second-degree relatives across four generations.</p> <p><bold>Results.</bold> It was found that identical variants of the nucleotide sequence, c.598_612del and c.1746-20C&gt;G, identified in the CAPN3 gene of the proband and her daughter, are in the trans position (compound heterozygous state), causing autosomal recessive calpain-3-related LGMD. This is an example of an incredibly rare pseudodominant inheritance of an autosomal recessive disease, established through indirect evidence that the proband’s husband is a heterozygous carrier of a nucleotide substitution in the CAPN3 gene.</p> <p><bold>Conclusion. </bold>It is crucial to examine the marriage partner for heterozygous carrier status of a gene mutation responsible for the disease in family planning and when clarifying the child’s prognosis for a patient with an autosomal recessive disease. Considering the existence of a late-onset (after 30 years) LGMD phenotype associated with the CAPN3 gene, differential diagnosis should begin with testing this gene in families with late disease onset.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> В группе поясно-конечностных мышечных дистрофий (ПКМД), включающей более 30 форм и обусловленных мутациями в генах, локализованных на аутосомах, наиболее распространённой является кальпаин-3-связанная ПКМД с аутосомно-рецессивным типом наследования (OMIM 253600). Наряду с этим предполагается существование доминантно наследуемой формы ПКМД (OMIM 618129), причиной развития которой является гетерозиготная мутация c.643_663del в гене CAPN3.</p> <p><bold>Цель</bold> работы — представить описание семейного случая ПКМД, обусловленной мутациями в гене CAPN3, с псевдодоминантным типом наследования.</p> <p><bold>Материалы и методы.</bold> Объект исследования — 2 больных ПКМД: женщина 59 лет и её дочь 38 лет. Использовались клинико-генеалогический и молекулярно-генетические методы: таргетная MPS-панель «Поясно-конечностные мышечные дистрофии», секвенирование по Сенгеру ДНК пробанда, её больной дочери и 6 родственников 1-й и 2-й степеней родства из 4 поколений.</p> <p><bold>Результаты.</bold> Установлено, что идентичные варианты нуклеотидной последовательности c.598_612del и c.1746-20C&gt;G, выявленные у пробанда и её дочери в гене CAPN3, находятся в транс-положении (компаунд-гетерозиготном состоянии) и являются причиной развития аутосомно-рецессивной кальпаин-3-связанной ПКМД. Это пример редчайшего феномена псевдодоминантного наследования аутосомно-рецессивного заболевания, установленного в результате получения косвенных данных о гетерозиготном носительстве одной из нуклеотидных замен в гене CAPN3 мужем пробанда.</p> <p><bold>Заключение.</bold> При планировании деторождения и уточнении прогноза потомства в семье больного с аутосомно-рецессивным заболеванием необходимо обследовать брачного партнера на наличие гетерозиготного носительства мутации в гене, ответственном за развитие болезни. Учитывая существование позднего (после 30 лет) фенотипа ПКМД, связанного с геном CAPN3, при уточнении диагноза в семьях с поздней манифестацией дифференциально- диагностический поиск следует начинать с тестирования этого гена.</p></trans-abstract><kwd-group xml:lang="en"><kwd>limb-girdle muscular dystrophy</kwd><kwd>autosomal recessive LGMD</kwd><kwd>calpainopathy</kwd><kwd>calpain-3-related muscular dystrophy</kwd><kwd>CAPN3 gene</kwd><kwd>pseudodominant inheritance</kwd><kwd>case report</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>поясно-конечностные мышечные дистрофии</kwd><kwd>аутосомно-рецессивные ПКМД</kwd><kwd>кальпаинопатия</kwd><kwd>кальпаин-3-связанная мышечная дистрофия</kwd><kwd>ген CAPN3</kwd><kwd>псевдодоминантный тип наследования</kwd><kwd>клинический случай</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Walton J.N., Nattrass F.J. On the classification, natural history and treatment of the myopathies. Brain. 1954;77(2):169–231. DOI: 10.1093/brain/77.2.169. PMID: 13190076.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Nonaka I. Muscular dystrophy: advances in research works and therapeutic trials. Rinsho Shinkeigaku. 2004;44(11):901–904. PMID: 15651326.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Straub V., Murphy A., Udd B. et al. 229th ENMC international workshop: Limb girdle muscular dystrophies — nomenclature and reformed classification, Naarden, the Netherlands, 17-19 March 2017. Neuromusc Disord. 2018;28(8):702–710. DOI: 10.1016/j.nmd.2018.05.007. PMID: 30055862.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Erb W. Dystrophia muscularis progressiva. Klinische und pathologisch anatomische Studien. Dtsch Nervenh. 1891;1:13 DOI: 10.1007/BF01669210.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Nigro V., Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol. 2014;33(1):1–12. PMID: 24843229.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Benarrocha L., Bonne G., Rivier F., Hamroun D. The 2020 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2019;29(12):980–1018. DOI: 10.1016/j.nmd.2019.10.010. PMID: 31791870.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Dincer P., Leturcq F., Richard I. et al. A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey. Ann Neurol. 1997; 42(2):222–229. DOI: 10.1002/ana.410420214. PMID: 9266733.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fanin M., Duggan D.J., Mostacciuolo M.L. et al. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet. 1997;34(12):973–977. DOI: 10.1136/jmg.34.12.973. PMID: 9429136.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bashir R., Britton S., Strachan T. et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet. 1998;20(1):37–42. DOI: 10.1038/1689. PMID: 9731527.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Urtasun M., Saenz A., Roudaut C. et al. Limb-girdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). Brain 1998;121(Pt 9):1735–1747. DOI: 10.1093/brain/121.9.1735. PMID: 9762961.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Norwood F.L., Harling C., Chinnery P.F. et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009; 132(Pt 11):3175–3186. DOI: 10.1093/brain/awp236. PMID: 19767415.</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Dadali E.L., Shagina O.A., Ryzhkova O.P. et al. Clinical-genetic characteristics of limb girdle-muscular dystrophy type 2A. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2010;110(4):79–83. PMID: 20517216. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Дадали Е.Л., Щагина О.А., Рыжкова О.П. и др. Клинико-генетические характеристики поясно-конечностной мышечной дистрофии 2А типа. Журнал неврологии и психиатрии им. C.C. Корсакова. 2010;110(4):79–83.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Hicks D., Sarkozy A., Muelas N. et al. A founder mutation in Anoctamin 5 is a major cause of limb girdle muscular dystrophy. Brain. 2011;134(Pt 1):171–182. DOI: 10.1093/brain/awq294. PMID: 21186264.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Vissing J., Barresi R., Witting N. et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain. 2016;139(Pt 8):2154–2163. DOI: 10.1093/brain/aww133. PMID: 27259757.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Fanin M., Nascimbeni A.C., Fulizio L., Angelini C. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord. 2005; 15(3):218–224. DOI: 10.1016/j.nmd.2004.11.003. PMID: 15725583.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Todrova A., Tournev I., Ninova N. et al. Screening for C283Y gamma-sarcoglycan mutation in a high-risk group of Bulgarian Gypsies: evidence for a geographical localization and a non-random distribution among Gypsy subgroups. Community Genet. 2002;5(4):217–221. DOI: 10.1159/000066687. PMID: 14960875.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kefi M., Amouri R., Driss A. et al. Phenotype and sarcoglycan expression in Tunisian LGMD 2C patients sharing the same del521-T mutation. Neuromuscul Disord. 2003;13(10):779–787. DOI: 10.1016/s0960-8966(03)00136-6. PMID: 14678800.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Spengos K., Walter M.C., Dekomien G. et al. C283Y mutation in the gamma-sarcoglycan gene in Greek Gypsies with severe limb girdle muscular dystrophy. Eur J Neurol. 2010;17(6):e41–e42. DOI: 10.1111/j.1468-1331.2010.03004.x. PMID: 20345928.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Piluso G., Politano L., Aurino S. et al. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet. 2005;42(9):686–693. DOI: 10.1136/jmg.2004.028738. PMID: 16141003.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zatz M., Starling A. Calpains and disease. N Engl J Med. 2005;352(23):2413–2423. DOI: 10.1056/NEJMra043361. PMID: 15944426.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Guglieri M., Magri F., D’Angelo M.G. et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat. 2008;29(2):258–266. DOI: 10.1002/humu.20642. PMID: 17994539.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Richard I., Broux O., Allamand V. et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995;81(1):27–40. DOI: 10.1016/0092-8674(95)90368-2. PMID: 7720071.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Martinez-Thompson J.M., Niu Z., Tracy J. A. et al. Autosomal dominant calpainopathy due to heterozygous CAPN3 c.643_663del21. Muscle Nerve. 2018;57(4):679–683. DOI: 10.1002/mus.25970. PMID: 28881388.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Häffner K., Speer A., Hübner C. et al. A small in-frame deletion within the protease domain of muscle-specific calpain, p94 causes early-onset limb-girdle muscular dystrophy 2A. Hum Mutat. 1998;Suppl 1:S298–S300. DOI: 10.1002/humu.1380110193. PMID: 9452114.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Dam L.T., Frankhuizen W.S., Linssen W.H.J.P. et al. Autosomal recessive limb-girdle and Miyoshi muscular dystrophies in the Netherlands: The clinical and molecular spectrum of 244 patients. Clin Genet. 2019;96(2):126–133. DOI: 10.1111/cge.13544. PMID: 30919934.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Krahn M., Pécheux C., Chapon F. et al. Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic deletion and evidence for messenger RNA decay. Clin Genet. 2007;72(6):582–592. DOI: 10.1111/j.1399-0004.2007.00906.x. PMID: 17979987.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Abouelhoda M., Faquih T., El-Kalioby M., Alkuraya F.S. Revisiting the morbid genome of Mendelian disorders. Genome Biol. 2016;17(1):235. DOI: 10.1186/s13059-016-1102-1. PMID: 27884173.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Avila J.D., Lacomis D. Neuromuscular Pathology Case. J Clin Neuromuscul Dis. 2015;17(1):30–33. DOI: 10.1097/CND.0000000000000090. PMID: 26301378.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Reddy H.M., Cho K.A., Lek M. et al. The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States. J Hum Genet. 2017;62(2):243–252. DOI: 10.1038/jhg.2016.116. PMID: 27708273.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Harris E., Topf A., Barresi R. et al. Exome sequences versus sequential gene testing in the UK highly specialised Service for Limb Girdle Muscular Dystrophy. Orphanet J Rare Dis. 2017;12(1):151. DOI: 10.1186/s13023-017-0699-9. PMID: 28877744.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Arrigoni F., De Luca A., Velardo D. et al. Multiparametric quantitative MRI assessment of thigh muscles in limb-girdle muscular dystrophy 2A and 2B. Muscle Nerve. 2018;58(4):550–558. DOI: 10.1002/mus.26189. PMID: 30028523.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Peric S., Stevanovic J., Johnson K. et al. Phenotypic and genetic spectrum of patients with limb-girdle muscular dystrophy type 2A from Serbia. Acta Myol. 2019;38(3):163–171. PMID: 31788660.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Bushby K.M., Beckmann J.S. The limb-girdle muscular dystrophies-proposal for a new nomenclature. Neuromuscul Disord. 1995;5(4):337–343. DOI: 10.1016/0960-8966(95)00005-8. PMID: 7580247.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Nascimbeni A.C., Fanin M., Tasca E., Angelini C. Transcriptional and translational effects of intronic CAPN3 gene mutations. Hum Mutat. 2010;31(9):E1658–E1669. DOI: 10.1002/humu.2132. PMID: 20635405.</mixed-citation></ref></ref-list></back></article>
